An Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects with Advanced Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs PL 2258 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Piramal Enterprises
- 02 Sep 2014 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 31 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 May 2013 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center: 0C12-7).